NCNA vs. MRKR, LPCN, CARA, UNCY, PMN, RNXT, BOLT, IPA, VIRX, and APRE
Should you be buying NuCana stock or one of its competitors? The main competitors of NuCana include Marker Therapeutics (MRKR), Lipocine (LPCN), Cara Therapeutics (CARA), Unicycive Therapeutics (UNCY), ProMIS Neurosciences (PMN), RenovoRx (RNXT), Bolt Biotherapeutics (BOLT), ImmunoPrecise Antibodies (IPA), Viracta Therapeutics (VIRX), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical preparations" industry.
Marker Therapeutics (NASDAQ:MRKR) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations.
22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 17.4% of Marker Therapeutics shares are owned by company insiders. Comparatively, 31.2% of NuCana shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
NuCana received 177 more outperform votes than Marker Therapeutics when rated by MarketBeat users. Likewise, 67.57% of users gave NuCana an outperform vote while only 63.39% of users gave Marker Therapeutics an outperform vote.
NuCana has a net margin of 0.00% compared to NuCana's net margin of -142.62%. NuCana's return on equity of -39.89% beat Marker Therapeutics' return on equity.
Marker Therapeutics has higher revenue and earnings than NuCana.
In the previous week, Marker Therapeutics and Marker Therapeutics both had 3 articles in the media. NuCana's average media sentiment score of 1.07 beat Marker Therapeutics' score of 0.90 indicating that Marker Therapeutics is being referred to more favorably in the media.
Marker Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, NuCana has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.
Marker Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 179.90%. NuCana has a consensus target price of $125.00, suggesting a potential upside of 3,343.53%. Given Marker Therapeutics' higher probable upside, analysts clearly believe NuCana is more favorable than Marker Therapeutics.
Summary
NuCana beats Marker Therapeutics on 7 of the 13 factors compared between the two stocks.
Get NuCana News Delivered to You Automatically
Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
